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Abstract 
Despite the effectiveness of endocrine therapies in estrogen receptor positive (ER+) breast 
cancer, approximately 40% of patients relapse. Previously, we identified the Focal-adhesion 
kinase canonical pathway as a major contributor of resistance to estrogen deprivation and 
cellular-sarcoma kinase (c-src) as a dominant gene in this pathway. Dasatinib, a pan-src inhibitor, 
has recently been used in clinical trials to treat ER+ patients but has shown mixed success. In the 
following study, using isogenic cell line models, we provide a potential explanation for these 
findings and suggest a sub-group that may benefit. A panel of isogenic cell lines modelling 
resistance to aromatase inhibitors (LTED) and tamoxifen (TAMR) were assessed for response to 
dasatinib ± endocrine therapy. Dasatinib caused a dose-dependent decrease in proliferation in 
MCF7-TAMR cells and resensitized them to tamoxifen and fulvestrant but not in HCC1428-
TAMR. In contrast, in estrogen-deprived conditions, dasatinib increased the proliferation rate of 
parental-MCF7 cells and had no effect on MCF7-LTED or HCC1428-LTED. Treatment with 
dasatinib caused a decrease in src-phosphorylation and inhibition of downstream pathways, 
including AKT and ERK1/2 in all cell lines tested, but only the MCF7-TAMR showed a 
concomitant decrease in markers of cell cycle progression. Inhibition of src also caused a 
significant decrease in cell migration in both MCF7-LTED and MCF7-TAMR cells. Finally, we 
showed that, in MCF7-TAMR cells, in contrast to tamoxifen sensitive cell lines, ER is expressed 
throughout the cell rather than being restricted to the nucleus and that treatment with dasatinib 
resulted in nuclear shuttling of ER, which was associated with an increase in ER-mediated 
transcription. These data suggest that src has differential effects in endocrine-resistant cell lines, 
particularly in tamoxifen resistant models, with low ER genomic activity, providing further 
evidence of the importance of patient selection for clinical trials testing dasatinib utility in ER+ 
breast cancer. 
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Introduction 
Over 80% of breast cancers (BC) are estrogen receptor (ER) positive (+) at primary diagnosis. 
Estrogen (E) mediates its effects by binding to the ER. E-bound ER associates classically with E-
response-elements (EREs) on target genes controlling proliferation and cell survival. ER has also 
been shown in-vitro to function via non-genomic mechanisms by association with growth factor 
signalling pathways (1).  
 
The reliance of ER+ tumours on E has been exploited clinically by the development and use of 
various endocrine therapies, such as: aromatase inhibitors (AI), which block the conversion of 
androgens to estrogens; selective ER modulators (SERM), such as tamoxifen, which compete 
with E for the ER; and fulvestrant (ICI182780), which once bound, potentiates degradation of ER 
(2). Despite the effectiveness of these current therapies, BC cells can circumvent the need for 
steroid hormones and resistance commonly occurs in approximately 40% of women, prioritizing 
the need to identify therapies to overcome this.  
 
Using global gene expression data derived from cells adapted to long-term-E-deprivation 
(LTED), we showed that the Focal adhesion kinase (FAK) pathway, was one of the major 
pathways upregulated at the point of resistance and revealed cellular sarcoma kinase (c-src), as 
the major gene elevated in this pathway (3).  
 
Src family kinases interact with a plethora of cellular cytosolic, nuclear and membrane proteins 
and modify these proteins by phosphorylation on tyrosine residues. Previous studies have alluded 
to the role of src in endocrine-resistant BC. For instance, the interaction between ER, src and the 
p85 subunit of PI3K leads to phosphorylation of AKT and ERK1/2, resulting in recruitment of 
PELP/MNAR to the ER nuclear transcription complex, promoting cell proliferation (4-6). 
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Previous studies have also shown that increased src activity after long-term treatment with 
tamoxifen enhances cellular invasion and motility in BC cells (7) and that impeding src activity 
reverses tamoxifen resistance (8).  
 
Taken together, these data provide support for the role of src signalling in endocrine-resistant BC 
and provide a rationale for inhibiting src signalling in combination with endocrine therapy to 
circumvent or delay the development of endocrine-resistance. 
 
Dasatinib is a potent orally available inhibitor of multiple oncogenic tyrosine kinases including 
the src family (9). Recently, clinical trials using single agent dasatinib in solid tumors have 
shown limited activity (10-12). The use of dasatinib in combination with endocrine therapy has 
also been investigated, however, dasatinib with fulvestrant or exemestane, did not show any 
benefit in progression free survival (PFS) for women with metastastic BC. In contrast, in a 
second study, the combination of dasatinib and letrozole did show improved PFS in women with 
ER+, HER2- metastastic BC  (reviewed by(13)). In the following manuscript, we provide an 
explanation for these conflicting findings, highlighting the need for careful patient selection, in 
order to gain maximum clinical benefit from such combination therapies. 
 
Material and Methods 
Antibodies and reagents 
Primary antibodies against phospho-srctyr416, phospho-srctyr527, src, phospho-ERK1/2 (p42/44), 
phospho-p90rsk, phospho-AKTser473, total-AKT, cyclin D1, phospho-EGFRtyr1068, total-EGFR and 
total p27 were purchased from Cell Signalling; total-ER and phospho-p27ser10 from Santa Cruz; 
total ERK1/2 and Actin (Sigma Aldrich) and PgR (Novacastra). Total-ERBB2 and phospho-
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ERBB2Tyr1248 were purchased from Millipore. Secondary horseradish peroxidase antibodies were 
obtained from Dako. 17-β-estradiol (E2) and 4-hydroxytamoxifen (4-OHT) were purchased from 
Sigma-Aldrich, UK; fulvestrant (ICI182780) from Tocris Bioscience and dasatinib from 
Selleckchem. 
 
Tissue Culture 
MCF7 and HCC1428 cells were obtained from the American Type Culture Collection (ATCC, 
Rockville, USA) and cultured in phenol red-free RPMI1640 medium supplemented with 10% 
fetal bovine serum and 1nM estradiol (E2). All cell lines were banked in multiple aliquots to 
reduce the risk of phenotypic drift and identity confirmed by short tandem repeat profiling 
(Promega, Madison, WI, USA). Long-term-estrogen-deprived cells (MCF7-LTED and 
HCC1428-LTED) modelling resistance to an AI were cultured in phenol red free RPMI 1640 
supplemented with 10% DCC-FBS (14). MCF7-TAMR and matched MCF7 cells were 
maintained in DMEM-F12 lacking phenol red and supplemented with 1% FBS and containing 
100nM 4OHT, as previously described (15), (16). The parental cell line was referred to as 
1%MCF7 and is a recognised model which is refractory to E2 but sensitive to tamoxifen and 
fulvestrant (15), (17), HCC1428-TAMR were cultured in the presence of 0.01nM E2 and 100nM 
4-OHT. Cells were stripped of E2 or 4-OHT for 3 days prior to experimentation.  
 
Proliferation assays 
Cells lines were seeded in 96-well plates. Monolayers were allowed to acclimatise for 24-hours 
prior to treatment with drug concentrations and combinations, as indicated, for 6-days with a 
medium change on day 3. Cell viability was determined using CellTitre-Glo® Luminescent Cell 
Viability Assay (Promega), according to the manufacture’s instructions.  
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Transcriptional assays 
Cell lines were seeded in 24-well plates and allowed to acclimatise for 24 hours. Subsequently, 
monolayers were transfected using TransIT-LT1 transfection reagent (Mirus) with 0.1µg of ER 
reporter construct (EREtkluc) and 0.1µg of pCH110 overnight. The following day, cells were 
treated with the drug combinations specified and left for 24-hours. Luciferase (Promega) and β-
galactosidase (GalactoStar, Applied Biosystems) activities were measured using a luminometer 
(VICTOR™ X5 Multilabel Plate Reader). Each experiment was performed 3 times with 3-4 
replicates per treatment.  
 
Western Blotting 
Cells were seeded into dishes and allowed to attach overnight. Monolayers were treated with the 
desired drug combinations for the required length of time. Whole-cell extracts were generated, as 
described previously (14). Densitometric evaluation was performed using ImageJ. 
 
Real-time quantitative PCR 
mRNA was extracted from treated cells using the RNeasy Mini kit (Qiagen) according to the 
manufacturers instructions and quantified using the Agilent2100 Bioanalyzer (Expert Software 
version B.02.03) with RNA Nano LabChip Kits (Agilent Technologies, Wokingham, Berkshire, 
UK). Total RNA was reverse transcribed using SuperScript III (Invitrogen) and random primers, 
in accordance with the manufacturer's instructions. qRT-PCR was performed in triplicate using 
the ABI Perkin-Elmer Prism 7900HT Sequence detection system (Applied Biosystems). Taqman 
gene expression assays (Applied Biosystems) were used to detect expression of uPA 
(Hs01547051_m1) and Caveolin-1 (Hs00971716_m1), together with FKBP15 
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(Hs00391480_m1), as a housekeeping gene, to normalise the data. The relative quantity was 
determined using ΔΔct according to the manufacturer's instructions (Applied Biosystems).  
 
Cell migration assay  
Boyden chambers (8µm pores) were placed into 24-well plates containing normal growth media 
and 10ng/ml EGF, as a chemo attractant. MCF7-LTED and MCF7-TAMR cells were pre-treated 
with 100nM dasatinib for 1-hour and then seeded at a density of 5x104 in the upper chamber in 
serum free media for 48-hours. Non-migrating cells were scraped from the top surface of the 
membrane while migrated cells were stained with Harris’ Haematoxylin (VWR). The membranes 
were excised and mounted on a microscope slide and the number of migrating cells counted. 
 
Immunofluorescence and confocal microscopy 
Cells were seeded on glass coverslips in basal media and treated for 24-hours with vehicle or 
100nM dasatinib, as indicated. Monolayers were fixed with 4% paraformaldehyde in PBS for 15 
minutes and permeabilized with 0.5% triton X100 for 10 minutes. Cells were subsequently 
blocked with PBS containing 1%BSA and 2%FBS and incubated with primary antibodies against 
psrctyr416 (Cell Signalling) and ER (Santa Cruz) for 2-hours. Cells were incubated with Alexa 
fluor 488 or 546 (red)-labelled secondary antibodies (Molecular Probes) for 1-hour and nuclei 
counterstained with DAPI (Invitrogen). Coverslips were finally mounted onto glass slides using 
vectashield-mounting media (Vector Labs) and images collected on the Zeiss LSM710 confocal 
microscope. 
 
 
 
 
	   8	  
Statistical Analysis 
Statistical analysis was conducted using one-way and two-way ANOVA to assess the 
significance of either escalating concentrations of dasatinib or the combination effects with other 
endocrine agents. Student’s t-test was used for the qRT-PCR, migration and transcription assays.  
 
Results 
Differential sensitivity of isogenic cell lines to dasatinib 
Src is regulated by phosphorylation of two tyrosine residues, which have opposing effects. 
Tyrosine 416 in the activation loop of the src kinase domain increases enzyme activity, whilst 
phosphorylation of tyrosine 527 by Csk reduces activity of the enzyme. Dasatinib is know to 
target both phosphorylated sites (18). Assessment of the expression of src in a panel of isogenic 
cell lines modelling resistance to E-deprivation (MCF7-LTED, HCC1428-LTED) or tamoxifen 
(MCF7-TAMR, HCC1428-TAMR) showed a marked increase in total src expression in MCF7 
models of endocrine resistance, in contrast to a decrease seen in the HCC1428 derivatives. 
Concordant expression levels of phosphorylated src were also evident (Supplementary Fig S1A). 
Based upon this finding, all cell lines were treated with escalating doses of dasatinib in the 
presence or absence of 0.01nM E2 (Figs 1A and 1B). Increasing concentrations of dasatinib 
showed no effect on proliferation in wt-MCF7 cells in the presence of E2, however, strikingly, in 
the absence of E2, dasatinib caused a 2-fold dose-dependent increase in proliferation (p<0.0001). 
MCF7-LTED showed no significant response to the antiproliferative effect of dasatinib in the 
presence or absence of E2 compared to vehicle control (Fig 1A). In contrast, the 1%MCF7 cell 
line, showed a slight but noticeable concentration dependent decrease in proliferation (p<0.0001), 
although this did not reach an IC50 value even at concentrations as high as 1000nM. The MCF7-
TAMR cell line showed the highest degree of sensitivity with an IC50 of c.25nM (p<0.0001) (Fig 
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1B). Of note, the wt-HCC1428, as well as the LTED and TAMR derivatives, which showed low 
src expression, were refractory to the inhibitory effect of dasatinib (Supplementary Figs S1A and 
S1B) suggesting this pathway may not play a significant role in these cell lines. 
 
We further assessed the effect of dasatinib in combination with increasing concentrations of 4-
OHT (Figs 1C and 1D; Supplementary Fig S1C) and fulvestrant  (Figs 1E and 1F). 4-OHT and 
fulvestrant caused a dose-dependent decrease in proliferation of wt-MCF7 and MCF7-LTED. 
Addition of dasatinib reduced the sensitivity of wt-MCF7 cells to the antiproliferative effect of 4-
OHT by 10-fold (1nM to 10nM, p<0.0001), but showed no significant added or deleterious effect 
in the MCF7-LTED (Fig 1C). No additional benefit of the combination of fulvestrant with 
dasatinib was observed in MCF7-LTED, however in wt-MCF7 although no marked benefit was 
evident, a statistical difference was detected (p<0.0001) (Fig 1E). As expected, the proliferation 
of the MCF7-TAMR cell line was unaffected by escalating concentrations of 4-OHT, however, 
the addition of dasatinib re-sensitised to the SERM (IC50 1000nM, p<0.0001). 1%MCF7 cells 
showed no significant additional benefit of the combination of 4-OHT with dasatinib (Fig 1D). 
Finally, we evaluated the effect of fulvestrant in combination with dasatinib in 1%MCF7 and 
TAMR cell lines. Both cells lines showed increased sensitivity to fulvestrant when combined 
with dasatinib (IC50 8nM to 1nM in 1%MCF7, p=0.0003 vs. 100nM to 5nM in TAMR, 
p<0.0001) (Fig 1F). In contrast to these observations, HCC1428-TAMR showed no response to 
4-OHT in the presence or absence of dasatinib (Supplemental Fig S1C) and were therefore 
excluded from further analysis. 
 
Effect of dasatinib and endocrine therapy on cell signalling 
pathways and cell cycle  
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In order to ascertain the effect of dasatinib in combination with endocrine agents on cellular 
signal transduction pathways, cells were treated with dasatinib alone and in combination with 4-
OHT or fulvestrant for 24-hours (Fig 2). Dasatinib alone caused a dose-dependent decrease in 
phosphorylation of src at tyrosine 416 and 527 in all cell lines tested (Supplementary Fig S1D). 
Of note, low concentrations of dasatinib (10nM) caused a slight but noticeable increase in  
psrctyr416 but not psrctyr527, suggesting the activation of a negative feedback loop, which is negated 
at higher concentrations.  
Based on this observation, together with our proliferation assays and previous publications (19), 
(20) we selected a concentration of 100nM for further in vitro studies. The combination of 
dasatinib with endocrine agents (4-OHT and fulvestrant) showed inhibition of src 
phosphorylation in all endocrine-sensitive and resistant cell lines. Expression of phosphorylated 
ERK1/2 and phosphorylated AKT was also inhibited by dasatinib ± the endocrine agents, but 
was most pronounced in the MCF7-TAMR cells, whilst total-ERK1/2 and AKT remained 
unchanged .  
We further assessed the effect of dasatinib on cell cycle markers. Dasatinib increased 
phosphorylation of p27 in wt-MCF7 in the absence of E2 and in combination with fulvestrant. 
Similarly, dasatinib caused a slight but noticeable increase in MCF7-LTED although this did not 
translate into a marked antiproliferative effect as seen in our combination studies. MCF7-TAMR 
cells following treatment with dasatinib showed significant increases in p27 phosphorylation 
together with a substantial down-regulation of cyclinD1, contrasting to the other cell lines tested 
(Fig 2 and Supplementary Fig. S2). These data are in keeping with the proliferation assays, which 
showed that dasatinib was most effective in the MCF7-TAMR cell line. 
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Dasatinib increases ER mediated transcription in isogenic cell lines 
We further analysed the effect of dasatinib on ER-mediated transactivation using an ERE-
luciferase-reporter construct. Dasatinib alone or in combination with the endocrine agents caused 
a significant increase in ER-mediated transactivation in both the MCF7-TAMR and 1%MCF7 
cells. This increase was also noted in the MCF7-LTED although this only met significance in the 
absence of exogenous E2 or in the presence of 4-OHT (Figs 3A-D). In keeping with the ER-
mediated transactivation data, PgR expression was increased by the addition of dasatinib in the 
absence of E2 in wt-MCF7 and MCF7-LTED. Similarly, dasatinib induced expression of PgR in 
the 1%MCF7 in the presence of both 4-OHT and fulvestrant. The MCF7-TAMR cells, in keeping 
with previous data (21), did not express PgR and this did not change with addition of dasatinib 
(Fig 3E and Supplementary Fig. S2).  
 
Expression of uPA and caveolin-1 are not biomarkers of sensitivity 
It has previously been reported, that sensitivity to dasatinib is dependent on BC subtype, with 
basal and post-epithelial-mesenchymal transition (EMT) BC cell lines, showing highest 
sensitivity (22, 23). Dasatinib sensitivity has also been associated with expression of caveolin-1 
and urokinase plasminogen activator (uPA) (22-26). To test the expression of these potential 
biomarkers, qRT-PCR was performed. MCF7-LTED and MCF7-TAMR cells both showed 
increased levels of uPA compared to their respective parental cell line. Expression of caveolin-1 
was also higher in the MCF7-LTED (Fig 4A). In contrast, 1%MCF7 and MCF7-TAMR showed 
no expression (data not shown). In accordance with previous data (23, 26), treatment with 
dasatinib reduced mRNA expression of both uPA and caveolin-1 (Supplementary Fig. S3), 
suggesting neither were the defining feature of sensitivity in these models. 
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Dasatinib inhibits migration of endocrine-resistant cell lines 
We further assessed the effect of dasatinib on the anti-migratory potential. Both MCF7-LTED 
and TAMR cells showed higher migratory capability when compared to their parental cell lines 
(5.3-fold versus 7.5-fold increase, respectively) (Fig 5A). Dasatinib caused a 40% reduction in 
the migration of MCF7-LTED and 73% in the MCF7-TAMR cells (Fig 5B).  
 
MCF7-LTED and MCF7-TAMR cells have similar baseline features 
but differ in the level of ER-mediated transactivation  
Having established that dasatinib had differential effects in the endocrine-resistant cell lines, we 
sought to investigate the similarities and differences between these isogenic models. Of note, the 
features of MCF7-LTED and MCF7-TAMR were concordant, both expressing higher levels of 
ERα, ERBB2, pERK1/2 and p90rsk compared to their parental control (Supplementary Fig 
S4A), but differed with regard to ER-mediated transactivation (14, 21). The MCF7-LTED 
showed a 7.8-fold increase in basal transcription compared to wt-MCF7 in the absence of E2, the 
MCF7-TAMR cells showed 5.6-fold lower level compared with the 1%MCF7 (Supplementary 
Fig S4B). Moreover, while MCF7-TAMR cells continue to express ERα similar to MCF7-
LTED, they lose the expression of PgR in support of their lower ER genomic activity 
(Supplementary Fig S4A).  
 
Dasatinib treatment results in nuclear shuttling of ER in MCF7-
TAMR cells 
We have previously shown that ER acts via a non-genomic mechanism in the MCF7-TAMR cells 
and that they appear to have an impeded luminal phenotype in relation to ER genomic function. 
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Contrastingly the wt-MCF7, MCF7-LTED and 1%MCF7 retain classical nuclear ER function 
(21) (Supplementary Fig S5). We, therefore hypothesised that src may be involved in cellular 
localisation of ER in the MCF7-TAMR phenotype. To test this, we treated 1%MCF7 and MCF7-
TAMR cells with dasatinib alone and in combination with 4-OHT. In the presence of 4-OHT 
alone, there was no change in the localisation of ER in MCF7-TAMR cells, whereas the 
combination of tamoxifen and dasatinib resulted in ER being shuttled into the nucleus (Fig 6A).  
 
Discussion 
Acquisition of endocrine-resistance is a common occurrence in BC patients and the identification 
of appropriate clinical interventions remains of paramount importance. Despite multiple drugged 
targets being proposed from in-vitro studies; data from resulting clinical trials has failed to meet 
expectation. For example, src activation has been associated with adaptation to both tamoxifen 
and LTED. Studies suggest that interaction between Cas and c-Src through pathways involving 
EGFR and signal transducer and activator of transcription 5b (STAT5b) are pivotal to this 
resistance mechanism (7, 27). Furthermore, Hiscox and colleagues have provided evidence that 
perturbation of src signalling reduces the invasive phenotype of tamoxifen resistant MCF7 cells 
(7).  To date, three predictive gene signatures derived from in vitro studies have been reported 
(24) (28) (29) but have failed to identify a group of BC patients for whom single agent dasatinib 
is effective (30). Of note, gene signatures do not necessarily take into consideration cellular 
context such as protein trafficking (31),  
 
Clinical trials assessing the combination of dasatinib with letrozole, exemestane or fulvestrant 
have provided mixed results. For instance, addition of dasatinib to fulvestrant or exemestane did 
not provide any benefit in PFS in women with metastatic BC (32, 33), in contrast Paul et al 
showed that the combination of letrozole and dasatinib increased PFS from 9.9 months in the 
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letrozole alone arm to 20.1 months in the combination (34). One explanation for these contrasting 
results, is the difference in the patient cohorts. In the trials investigating fulvestrant and 
exemestane, the majority of patients had relapsed on an AI, whilst those in Paul’s study had 
relapsed on tamoxifen. It is tempting to hypothesise, that the mechanism of resistance to the 
endocrine agent subsequently governs sensitivity to dasatinib. To investigate this further, we 
compared the effect of dasatinib in combination with endocrine therapy in a panel of isogenic 
cell lines modelling acquired resistance to either tamoxifen or LTED.  
 
In this study, we showed that dasatinib had different effects on endocrine-resistant and sensitive 
cell lines. Of note, in the absence of exogenous E (modelling patients receiving an AI) the 
addition of dasatinib promoted, rather than impeded the proliferation of wt-MCF7 cells and the 
same effect was seen with 4-OHT, suggesting the combination would be deleterious in the 
primary setting. A potential mechanism related to this observation is discussed below. 
Furthermore, no benefit was seen in MCF7-LTED suggesting the combination of dasatinib with 
E-deprivation, 4-OHT or fulvestrant would provide no further benefit in the metastatic setting. 
Similarly, HCC1428-LTED and HCC1428-TAMR were resistant to the antiproliferative effect of 
dasatinib, possibly as a result of the reduction in expression of src compared to wt-HCC1428. In 
contrast, dasatinib reduced the proliferation of the MCF7-TAMR cell line, increased sensitivity 
to fulvestrant and re-sensitised them to the antiproliferative effect of 4-OHT. These data were 
further supported by downstream analysis of cell cycle proteins, which showed that dasatinib 
increased phosphorylated p27 and decreased cyclinD1 most significantly in the MCF7-TAMR 
cell line. In contrast, both the wt-MCF7 and MCF7-LTED showed little difference when 
comparing single agent endocrine therapy with or without the addition of dasatinib,  
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Previous studies have associated over-expression of uPA and CAV1 with tamoxifen resistance 
(35-37) and as determinant of sensitivity to dasatinib, (22, 25).  However, no differential 
expression of uPA was evident between the two resistant cell lines and whilst the LTED showed 
a marked increase in expression of CAV1, the MCF7-TAMR showed no expression in keeping 
with previous studies (26, 38). Furthermore, both resistant cell lines showed an enhanced 
migratory phenotype compared to their parental line and in both cases dasatinib impeded 
migration to a similar degree.  
 
To address the discordance in the antiproliferative effect of dasatinib in the LTED versus the 
MCF7-TAMR cell line, we concentrated on differences in phenotype. Analysis showed that 
expression of key receptor tyrosine kinases and their downstream partners was consistent 
between the two resistant models. However, the MCF7-TAMR cell line showed over a 5-fold 
reduction in ER genomic activity and loss of PgR expression, whereas in the LTED model ER 
genomic activity was 5-fold higher than their parental control, although PgR expression was 
significantly reduced. This suggests that the ER in the LTED setting remains classical in its 
function as a genomic transcription factor.   
 
Previous studies have provided support for interplay between ER and src, resulting in 
phosphorylation of the ER at tyrosine 537 and promoting nuclear export. Inhibition of src negates 
this effect, leading to sequestration of ER in the nucleus (39, 40). This could account for the 
growth promoting effect of dasatinib in the wt-MCF7 in the absence of E2, allowing the retained 
nuclear receptor to continue to bind EREs promoting cell survival. This increase in transcription 
was also observed in the MCF7-TAMR cell line although it appeared insufficient to overcome 
upstream inhibitory effects on ERK1/2 and AKT leading to an overall drop in proliferation. One 
explanation for this is due to the cellular context. For instance, src and ER have been shown to 
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interact at the cell membrane in complex with PELP-1 and PI3K, leading to activation of the 
ERK1/2 and AKT pathways (41, 42). To address this, we performed confocal microscopy of ER 
in the LTED and MCF7-TAMR setting and showed that whilst ER in the LTED cells remained 
nuclear, in the MCF7-TAMR cell line it was both membranous and cytoplasmic. Treatment of 
the MCF7-TAMR cells with the combination of dasatinib and 4-OHT resulted in nuclear 
shuttling of ER, potentially allowing it to become a classical target for 4-OHT, which associated 
with a decrease in pAKT and pERK1/2, together with a significant reduction in proliferation.  
 
Taken together, these data suggest that the mode of resistance influences sensitivity to dasatinib, 
and those tumours with an impeded luminal phenotype, in relation to ER-genomic function are 
most likely to respond (Fig 6B). This provides further evidence of the importance of patient 
selection for clinical trials testing dasatinib utility in ER-positive BC. 
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Figure Legends 
Figure 1: Antiproliferative effects of dasatinib alone or in combination with endocrine 
agents. Cells were treated with increasing concentrations of dasatinib (A,B), or fixed 
concentration of dasatinib and increasing concentrations of 4-OHT (C,D) or fulvestrant (ICI) 
(E,F) for 6-days with a medium change at day 3. Cell viability was determined using CellTitre-
Glo® Luminescent Cell Viability Assay. The data are representative of three independent 
experiments (Error bars represent ± SEM).  
 
Figure 2: Analysis of src and downstream signalling in response to dasatinib combined with 
endocrine agents. Wt-MCF7, MCF7-LTED, 1%MCF7 and MCF7-TAMR cells were treated for 
24-hours with the drug combinations mentioned above. Standard concentrations of dasatinib 
(100nM), E2 (0.01nM), 4-OHT (10nM) and fulvestrant (ICI) (10nM) were used. Whole-cell 
extracts were assessed for expression of various proteins indicated using immunoblotting. 
Figures below each panel represent semi-quantitave changes in protein expression relative to 
actin. 
 
Figure 3: Effects of dasatinib on ER-mediated transcription and ER signalling. Cell lines 
were co-transfected with EREIItkLuc and pCH110 and treated with the combinations mentioned 
(A, B, C, D). Standard concentrations of dasatinib (100nM), E2 (0.01nM), 4-OHT (10nM) and 
fulvestrant (ICI) (10nM), were used. Normalized luciferase activity from triplicate wells was 
expressed relative to the vehicle-treated control. Bars represent ± SEM. *p<0.05, **p<0.01, 
***p<0.001. Effects were confirmed in three independent experiments. Wt-MCF7, MCF7-
LTED, 1%MCF7 and MCF7-TAMR cells were treated as indicated for 24-hours, with the same 
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amounts as stated above. Western blot was used to assess changes in total ER and PgR. Figures 
below each panel represent semi-quantitave changes in protein expression relative to actin.(E).  
 
Figure 4: Expression of uPA and Caveolin-1 in endocrine-resistant versus sensitive cell 
lines. Assessment of mRNA relative expression of uPA and Caveolin-1 using qPCR in wt-
MCF7, MCF7-LTED, 1%MCF7 and MCF7-TAMR cell lines. Bars represent ± SEM. *p<0.05, 
**p<0.01, ***p<0.001. 
 
Figure 5: Effect of dasatinib on basal migration. Migratory capacity of endocrine-resistant cell 
lines (MCF7-LTED and MCF7-TAMR) compared to endocrine-sensitive cells lines (wt-MCF7 
and 1%MCF7, respectively) (A); Effect of dasatinib upon migratory capacity in MCF7-LTED 
and MCF7-TAMR cell lines (B). Bars represent ± SEM. *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 6: Dasatinib promotes nuclear shuttling of ER in the MCF7-TAMR cells but not the 
1%MCF7. 1%MCF7 and MCF7-TAMR cells were treated for 24-hours with 1%FBS, dasatinib 
(100nM), 4-OHT (10nM), or the combination and stained with ER, pSrctyr416 and DAPI; bars 
indicate 20µm (A). Schematic diagram showing cross-talk between non-genomic ER and Src. ER 
associates with Src at the cell membrane via a non-genomic mechanism. This leads to an increase 
in both ERK1/2 and AKT providing a survival advantage. The reduced genomic activity of ER in 
this setting enhances resistance to tamoxifen. Inhibition of Src with dasatinib causes ER to 
shuttle to the nucleus where it is targeted by tamoxifen, leading to a decrease in proliferation and 
re-sensitization to the endocrine agent (B). 
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Supplementary Figures 
S1. Src as a target of dasatinib. Expression of src in isogenic MCF7 and HCC1428 cell lines 
modelling resistance to LTED or tamoxifen (A). Effect of increasing concentrations of dasatinib 
on proliferation of wt-HCC1428, HCC1428-LTED and HCC1428-TAMR in the presence or 
absence of exogenous E2 (B) assessment of the addition of dasatinib to re-sensitise HCC1428-
TAMR to the antiproliferative effect of 4-OHT (C). Effect of increasing amounts of dasatinib 
upon phosphorylation and total src in wt-MCF7, MCF7-LTED, 1%MCF7 and MCF7-TAMR cell 
lines (D). Figures below each panel in the western blots represent semi-quantitave changes in 
protein expression relative to actin. 
 
S2. Densitometric analysis of three independent studies showing mean arbitrary changes relative 
to DCC or 1% controls. 
 
S3. Effect of dasatinib upon mRNA expression of uPA in wt-MCF7, MCF7-LTED (A); 
1%MCF7 and MCF7-TAMR cells (B); and Caveolin-1 in wt-MCF7 and MCF7-LTED cells (C). 
Bars represent ± SEM. *p<0.05, **p<0.01, ***p<0.001 
 
S4. Baseline expression of proteins in MCF7-LTED and MCF7-TAMR compared to their wt 
counterparts Figures below each panel represent semi-quantitave changes in protein expression 
relative to actin (A). ER/ERE transactivation in wt-MCF7, MCF7-LTED, 1%MCF7 and MCF7-
TAMR cells (B). Bars represent ± SEM. *p<0.05, **p<0.01, ***p<0.001. 
 
S5. ER localisation in wt-MCF7 versus MCF7-LTED derivatives under basal conditions, bars 
indicate 20µm. 
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